BTIG Believes GNMK Still Has Room to Grow

By Ryan Adsit

In a report issued on March 7, Karen Koski from BTIG reiterated a Buy rating on GenMark (NASDAQ: GNMK), with a price target of $17. The company’s shares closed yesterday at $12.04, close to its 52-week high of $13.43.

According to, Koski is a 5-star analyst with an average return of 12.9% and a 66.7% success rate. Koski covers the Healthcare sector, focusing on stocks such as Accelerate Diagnostics, Orasure Technologies, and Foundation Medicine.

Currently, the analyst consensus on GenMark is Strong Buy and the average price target is $15.30, representing a 27.1% upside.

In a report issued on February 28, Canaccord Genuity also reiterated a Buy rating on the stock with a $14 price target.

The company has a one year high of $13.43 and a one year low of $4.66. Currently, GenMark has an average volume of 285.5K.

Based on the recent corporate insider activity of 89 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Eric Stier, the SVP & GC of GNMK sold 307 shares for a total of $3,773.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

GenMark Diagnostics, Inc. is a molecular diagnostics company. The firm focuses on the development and commercializing of its its proprietary eSensor detection technology. It also manufactures, sells, and supports instruments and molecular tests. The company was founded by Jon Faiz Kayyem on February 12, 2010 and is headquartered in Carlsbad, CA.